Interpreting the RESET-RA 12-month outcomes: What matters for clinical decision-making

SetPoint Medical is preparing to present new clinical data at ACR Convergence 2025, adding momentum behind its implantable neuroimmune modulation treatment for rheumatoid arthritis. The data will include long-term clinical outcomes, MRI-based joint protection findings, and patient-centered evidence on therapy preference, underscoring growing interest in non-pharmaceutical treatment options for autoimmune disease. The presentation follows the July 2025 U.S. Food and Drug Administration approval of the SetPoint System for use in adults living with moderately to severely active rheumatoid arthritis who have an inadequate response, loss of response, or intolerance to biologic and targeted synthetic disease-modifying anti-rheumatic drugs.

The SetPoint System is designed to stimulate the vagus nerve to regulate inflammatory pathways in the body. The approach is based on the concept that the nervous system plays a central role in modulating immune activity. By activating this communication pathway, the therapy aims to reduce inflammatory signaling without the broad immune suppression associated with many biologic drugs and Janus kinase inhibitors. For patients who have cycled through multiple medications or continue to experience joint pain, stiffness, and fatigue despite therapy, the emergence of a drug-free intervention with sustained efficacy potential is a notable development in the rheumatoid arthritis care landscape.

Why is neuroimmune modulation gaining attention in rheumatoid arthritis treatment, and how does the SetPoint System differ from existing therapies?

For more than two decades, therapeutic progression in rheumatoid arthritis has centered around suppressing inflammatory cytokines and disrupting immune-mediated joint damage through targeted biological drug classes. While these therapies have changed the natural history of the disease for many patients, a significant proportion does not achieve sustained remission. Some experience diminishing response over time, while others face adverse effects ranging from mild infections to more serious immune-related complications.

Neuroimmune modulation takes a fundamentally different approach. Instead of blocking inflammatory molecules, it targets the signaling loops between the central nervous system and the immune system that control inflammatory balance. The vagus nerve, one of the largest autonomic nerves in the body, is known to influence cytokine production and inflammatory cascades. The SetPoint System delivers electrical stimulation to this nerve at calibrated intervals to restore an immunologic “setpoint” rather than inhibiting the immune response outright.

This positions the therapy as a mechanism of regulation, rather than suppression. For many patients, especially those concerned about long-term biologic exposure or those who have already cycled through multiple therapies, this difference matters—both medically and psychologically.

What clinical outcomes were observed in the RESET-RA study and how durable were the results over 12 months?

The RESET-RA study enrolled 242 adults with moderately to severely active rheumatoid arthritis who had previously received biologic or targeted synthetic disease-modifying anti-rheumatic drugs. The study was designed as a randomized, sham-controlled, double-blind trial. At the three-month mark, the SetPoint System demonstrated statistically significant improvements in American College of Rheumatology ACR20 responses. Importantly, these improvements did not plateau. Patients who continued therapy maintained and, in some cases, deepened their clinical response through 6, 9, and 12 months.

Measures such as the Disease Activity Score 28 using C-reactive protein and the Clinical Disease Activity Index showed that a meaningful proportion of patients reached low disease activity or remission by one year. Notably, most achieved this without adding further biologic or Janus kinase inhibitor therapy, indicating that the device provided sustained disease control as a standalone intervention. Therapy continuation rates were high, suggesting tolerability, treatment satisfaction, and sustained perceived benefit.

For clinicians evaluating long-term disease management strategies, durability of response is a core determinant of therapy value. The one-year outcomes presented by SetPoint Medical reinforce that neuroimmune modulation is not just a short-term symptom intervention but a potential sustained regulatory therapy.

How did MRI imaging results support the therapy’s role in slowing joint damage progression?

The imaging data presented from the study used RAMRIS scoring, a validated magnetic resonance imaging metric for tracking synovitis, osteitis, and joint erosion in rheumatoid arthritis. Among patients with an erosive phenotype at baseline, those who received active nerve stimulation experienced reduced erosion progression as early as three months. When patients initially in the control group crossed over to active therapy, their erosion progression slowed to similar levels.

This imaging evidence is significant. Historically, the ability to slow or halt joint erosion has been strongly associated with biologic and targeted DMARD therapies. Demonstrating that a device-based approach can contribute to structural joint protection broadens the therapeutic possibilities for rheumatologists. It also reinforces that neuroimmune modulation does not merely address symptoms but may help modify disease trajectory.

What does patient preference research indicate about demand for non-pharmaceutical treatment options?

A national patient survey assessing treatment perceptions revealed that only about one-third of patients reported satisfaction with their current therapy. Many expressed concerns regarding ongoing fatigue, functional limitations, and emotional strain arising from unpredictable flares. Among those who had previously been treated with biologics or Janus kinase inhibitors, interest in device-based therapy was particularly strong.

When asked to compare potential treatment choices, respondents valued improvements in pain, daily functioning, fatigue reduction, and long-term joint protection more strongly than maintaining drug-based treatment pathways. Early impressions of the SetPoint System were described as positive or extremely positive among nearly half of individuals surveyed.

This suggests growing openness to treatment modalities that supplement or replace pharmacological escalation and indicates that neuroimmune modulation may find a receptive patient base seeking new forms of control over their disease experience.

How might neuroimmune modulation fit into broader autoimmune care strategies going forward?

The implications of this therapy extend beyond rheumatoid arthritis. SetPoint Medical has signaled interest in exploring applications in multiple sclerosis and Crohn’s disease, where immune dysregulation and inflammatory signaling also play defining roles. The broader medical community is increasingly examining the interplay between the nervous and immune systems, and researchers across immunology, neurology, and rheumatology are tracking how these pathways may influence long-term disease control.

If neuroimmune modulation continues to demonstrate durable efficacy and favorable safety, it may evolve into a standard option for patients early in the treatment pathway, rather than a late-stage intervention. Future research may explore combination strategies, where device stimulation complements lower-dose pharmaceutical treatment to reduce cumulative exposure without compromising disease control.

The ACR Convergence 2025 presentations represent a moment where clinical evidence, patient preference, and mechanistic understanding are aligning to support a broader reconsideration of how autoimmune diseases can be managed. For many patients, that shift may translate to greater choice and more personalized care strategies.

What are the most important insights clinicians and patients should take away from the new SetPoint Medical data?

• The SetPoint System is the first FDA-approved neuroimmune modulation therapy designed to treat rheumatoid arthritis by stimulating the vagus nerve rather than suppressing immune function through pharmaceutical mechanisms.

• Twelve-month clinical results from the RESET-RA study showed sustained improvements in pain, swelling, disease activity scores, and functional outcomes without the need for additional biologic or Janus kinase inhibitor therapy for many patients.

• MRI-based findings demonstrated reduced progression of joint erosion in patients receiving neuroimmune stimulation, suggesting that the therapy may contribute to disease modification, not only symptom relief.

• National patient preference research reflected strong interest in non-pharmaceutical therapeutic approaches, especially among patients dissatisfied with biologic or JAK inhibitor response or tolerability.

• The outcomes presented at ACR Convergence 2025 position neuroimmune modulation as a distinct, durable therapeutic category that may expand into multiple autoimmune disease areas in the years ahead.